Lavipharm S.A (LAVI) — Strategic Asset Allocation Index
Lavipharm S.A (LAVI) has a Strategic Asset Allocation Index of 40.4% as of June 2023. Strategic assets (PP&E of €17.20 Million plus long-term investments of €-) total €17.20 Million, measured against net assets of €42.53 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See net asset quality index of Lavipharm S.A to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Lavipharm S.A Strategic Asset Allocation Index (2022–2022)
This chart shows how Lavipharm S.A's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of June 2023, the index stands at 40.4%, representing strategic assets of €17.20 Million against net assets of €42.53 Million EUR. For live market cap and overall valuation, see Lavipharm S.A (LAVI) total market value.
Annual Strategic Asset Allocation Index for Lavipharm S.A (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Lavipharm S.A from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Lavipharm S.A (LAVI) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 42.3% | €17.06 Million | €17.06 Million | €- | €40.28 Million | — |